Prognostic value of <scp>PSMA PET</scp> in predicting long‐term biochemical control following curative intent treatment for prostate cancer
PSMA SUV<sub>max</sub> is a strong predictor of BFFS in patients with non-metastatic prostate cancer who underwent curative intent treatment. Patients with low-risk disease on biopsy (ISUP 1-3) but high PSMA SUV<sub>max</sub> may have biochemical failure risk analogous to higher-risk disease (ISUP 4-5). These findings allow for further risk stratification and prognosis of patients with newly diagnosed prostate cancer planned for definitive treatment.
Authors
- Gishan Ratnayake (ORCID: https://orcid.org/0000-0003-4320-3601)
- Myles Webb
- Ahmed M. Mehdi (ORCID: https://orcid.org/0000-0002-9300-2341)
- Handoo Rhee (ORCID: https://orcid.org/0000-0002-1722-7127)
- Tanya Holt (ORCID: https://orcid.org/0000-0002-3895-0680)
- Angus Ades (ORCID: https://orcid.org/0009-0006-9285-002X)
Institutions
- Prostate Cancer Foundation of Australia (AU)
- The University of Queensland (AU)
- Princess Alexandra Hospital (AU)
- QCIF Ltd. (AU)
Publication Details
- Journal
- Journal of Medical Imaging and Radiation Oncology
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1111/1754-9485.13787
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Ipsen